Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia

Despite the success of the combination of venetoclax with the hypomethylating agents (HMA) decitabine or azacitidine in inducing remission in older, previously untreated patients with acute myeloid leukemia (AML), resistance - primary or secondary - still constitutes a significant roadblock in the q...

Descripción completa

Detalles Bibliográficos
Autores principales: Saliba, Antoine N., John, August J., Kaufmann, Scott H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8011583/
https://www.ncbi.nlm.nih.gov/pubmed/33796823
http://dx.doi.org/10.20517/cdr.2020.95

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8011583/
https://www.ncbi.nlm.nih.gov/pubmed/33796823
http://dx.doi.org/10.20517/cdr.2020.95

Ejemplares similares